Marshall Wace’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $97.1M | Buy |
492,446
+486,986
| +8,919% | +$93.9M | 0.1% | 174 |
|
|
2025
Q4 | $1M | Sell |
5,460
-342,787
| -98% | -$60.1M | ﹤0.01% | 1921 |
|
|
2025
Q3 | $53.4M | Sell |
348,247
-651,719
| -65% | -$98.6M | 0.05% | 300 |
|
|
2025
Q2 | $140M | Buy |
999,966
+311,951
| +45% | +$43.7M | 0.16% | 116 |
|
|
2025
Q1 | $101M | Sell |
688,015
-1,250,466
| -65% | -$181M | 0.13% | 136 |
|
|
2024
Q4 | $254M | Buy |
+1,938,481
| New | +$271M | 0.31% | 47 |
|
|
2024
Q3 | – | Sell |
-293,680
| Closed | -$45.8M | – | 2501 |
|
|
2024
Q2 | $45.8M | Sell |
293,680
-279,139
| -49% | -$42M | 0.06% | 283 |
|
|
2024
Q1 | $77.6M | Buy |
572,819
+552,432
| +2,710% | +$73.2M | 0.12% | 166 |
|
|
2023
Q4 | $2.75M | Buy |
20,387
+4,186
| +26% | +$544K | ﹤0.01% | 1098 |
|
|
2023
Q3 | $2.19M | Sell |
16,201
-100,256
| -86% | -$13.7M | ﹤0.01% | 1186 |
|
|
2023
Q2 | $16.7M | Sell |
116,457
-112,118
| -49% | -$16.5M | 0.03% | 543 |
|
|
2023
Q1 | $31.7M | Sell |
228,575
-940,045
| -80% | -$126M | 0.07% | 312 |
|
|
2022
Q4 | $158M | Buy |
1,168,620
+266,954
| +30% | +$33.5M | 0.36% | 52 |
|
|
2022
Q3 | $98.9M | Buy |
901,666
+153,783
| +21% | +$19.5M | 0.22% | 87 |
|
|
2022
Q2 | $98.8M | Sell |
747,883
-227,477
| -23% | -$29.8M | 0.2% | 103 |
|
|
2022
Q1 | $129M | Sell |
975,360
-43,965
| -4% | -$5.27M | 0.25% | 78 |
|
|
2021
Q4 | $119M | Buy |
1,019,325
+917,367
| +900% | +$108M | 0.22% | 86 |
|
|
2021
Q3 | $12.2M | Buy |
101,958
+60,127
| +144% | +$7M | 0.05% | 442 |
|
|
2021
Q2 | $5.01M | Sell |
41,831
-53,042
| -56% | -$5.82M | 0.02% | 831 |
|
|
2021
Q1 | $9.43M | Buy |
94,873
+79,151
| +503% | +$7.96M | 0.04% | 485 |
|
|
2020
Q4 | $1.57M | Buy |
+15,722
| New | +$1.67M | 0.01% | 1046 |
|
|
2020
Q3 | – | Sell |
-72,621
| Closed | -$7.68M | – | 1570 |
|
|
2020
Q2 | $7.68M | Buy |
72,621
+34,393
| +90% | +$3.55M | 0.05% | 354 |
|
|
2020
Q1 | $3.41M | Sell |
38,228
-512,868
| -93% | -$48.3M | 0.03% | 476 |
|
|
2019
Q4 | $55M | Sell |
551,096
-391,636
| -42% | -$36.9M | 0.38% | 48 |
|
|
2019
Q3 | $84M | Sell |
942,732
-229,973
| -20% | -$19.9M | 0.66% | 18 |
|
|
2019
Q2 | $96.8M | Buy |
1,172,705
+848,612
| +262% | +$66.5M | 0.8% | 14 |
|
|
2019
Q1 | $26.2M | Buy |
+324,093
| New | +$25.5M | 0.25% | 80 |
|
|
2018
Q3 | – | Sell |
-149,796
| Closed | -$10.5M | – | 1131 |
|
|
2018
Q2 | $10.5M | Buy |
+149,796
| New | +$10.8M | 0.16% | 176 |
|
|
2017
Q3 | – | Sell |
-101,717
| Closed | -$6.92M | – | 339 |
|
|
2017
Q2 | $6.92M | Buy |
+101,717
| New | +$6.64M | 0.3% | 66 |
|
|
2017
Q1 | – | Sell |
-326,261
| Closed | -$17.8M | – | 339 |
|
|
2016
Q4 | $17.8M | Buy |
326,261
+206,168
| +172% | +$11.7M | 0.12% | 212 |
|
|
2016
Q3 | $7.89M | Buy |
+120,093
| New | +$7.85M | 0.06% | 323 |
|
|
2015
Q4 | – | Sell |
-6,804
| Closed | -$433K | – | 970 |
|
|
2015
Q3 | $433K | Sell |
6,804
-35,972
| -84% | -$2.37M | 0.01% | 759 |
|
|
2015
Q2 | $2.73M | Sell |
42,776
-62,285
| -59% | -$4.26M | 0.04% | 408 |
|
|
2015
Q1 | $7.19M | Buy |
+105,061
| New | +$7.3M | 0.09% | 250 |
|
|
2014
Q3 | – | Sell |
-108,220
| Closed | -$8.04M | – | 875 |
|
|
2014
Q2 | $8.04M | Sell |
108,220
-366,345
| -77% | -$26.5M | 0.12% | 203 |
|
|
2014
Q1 | $30.8M | Buy |
+474,565
| New | +$30.6M | 0.56% | 44 |
|
Other funds holding AZN
IA
VCM
VAM
Marshall Wace's AZN Position: Q1 2026 in Review
Marshall Wace increased its AstraZeneca (AZN) stake by 8,919% in Q1 2026, buying an estimated $93.9M and bringing the position to 492,446 shares worth $97.1M. The position accounts for 0.1% of the portfolio, ranked #174.
Marshall Wace first reported a position in AZN in Q1 2014 and has held it in 36 quarters since. The position peaked at $254M in Q4 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Marshall Wace held 492,446 shares of AstraZeneca worth $97.1M as of Q1 2026.
- Marshall Wace bought 486,986 AstraZeneca shares in Q1 2026, an estimated $93.9M.
- AstraZeneca made up 0.1% of Marshall Wace's portfolio in Q1 2026, its #174 holding.
- Marshall Wace first reported a position in AstraZeneca in Q1 2014 and has held it in 36 quarters since.
- Marshall Wace's AstraZeneca position peaked at $254M in Q4 2024.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.